PL4482481T3 - Związki do zastosowania w leczeniu dystrofinopatii - Google Patents
Związki do zastosowania w leczeniu dystrofinopatiiInfo
- Publication number
- PL4482481T3 PL4482481T3 PL23705290.7T PL23705290T PL4482481T3 PL 4482481 T3 PL4482481 T3 PL 4482481T3 PL 23705290 T PL23705290 T PL 23705290T PL 4482481 T3 PL4482481 T3 PL 4482481T3
- Authority
- PL
- Poland
- Prior art keywords
- dystrophinopathy
- compounds
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/618—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
- A61K31/621—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate having the hydroxy group in position 2 esterified, e.g. benorylate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22382147.1A EP4230196A1 (en) | 2022-02-21 | 2022-02-21 | Compounds for use in the treatment of dystrophinopathies |
| PCT/EP2023/054140 WO2023156645A1 (en) | 2022-02-21 | 2023-02-20 | Compounds for use in the treatment of dystrophinopathies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4482481T3 true PL4482481T3 (pl) | 2026-03-23 |
Family
ID=80446433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL23705290.7T PL4482481T3 (pl) | 2022-02-21 | 2023-02-20 | Związki do zastosowania w leczeniu dystrofinopatii |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20250152567A1 (pl) |
| EP (2) | EP4230196A1 (pl) |
| JP (1) | JP2025508761A (pl) |
| KR (1) | KR20240150792A (pl) |
| CN (1) | CN118973560A (pl) |
| AU (1) | AU2023222467A1 (pl) |
| CA (1) | CA3244747A1 (pl) |
| DK (1) | DK4482481T3 (pl) |
| ES (1) | ES3061083T3 (pl) |
| IL (1) | IL315130A (pl) |
| MX (1) | MX2024010235A (pl) |
| PL (1) | PL4482481T3 (pl) |
| PT (1) | PT4482481T (pl) |
| WO (1) | WO2023156645A1 (pl) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025072685A1 (en) * | 2023-09-28 | 2025-04-03 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods thereof |
| WO2026020094A1 (en) * | 2024-07-18 | 2026-01-22 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Use of sr-4370 and analogs thereof for the treatment of muscle-related disorders |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3111517A (en) | 1959-01-06 | 1963-11-19 | Pfizer & Co C | Derivatives of 3, 4-dihydrobenzo-thiadiazine dioxides |
| BE637389A (pl) | 1962-09-13 | |||
| GB1063821A (en) | 1964-03-13 | 1967-03-30 | Vsesoiuzny Ni Sky Khim Farmats | Prednisone preparation |
| GB1101747A (en) | 1964-04-09 | 1968-01-31 | Sterwin Ag | Salicylamide derivatives |
| DE1270544B (de) | 1965-06-19 | 1968-06-20 | Beiersdorf Ag | 4-Chlor-5-sulfamylsalicylsaeure-(2', 6'-dimethyl)-anilid und dessen Alkali- oder Ammonium-Salze sowie Verfahren zu deren Herstellung |
| GB1176266A (en) | 1967-07-31 | 1970-01-01 | Kyowa Hakko Kogyo Kk | Process for Producing L-Citrulline |
| IT1044222B (it) | 1972-05-23 | 1980-03-20 | Zambeletti Spa L | Bifenilil alcanoilaminopiridine ad attivita anti infiammatoria di lunga durata |
| IT1088554B (it) | 1977-11-17 | 1985-06-10 | F I D I A Spa | Procedimento sellettivo per la preparazione di derivati della 7-indrossi cumarina |
| DE3069496D1 (de) | 1979-06-28 | 1984-11-29 | Takeda Chemical Industries Ltd | 2,3-dialkoxy-1,4-quinone derivatives; method of producing 1,4-quinone derivatives |
| US4749649A (en) | 1983-05-16 | 1988-06-07 | The Upjohn Company | Microbial Δ1-dehydrogenation process using a scavenger of toxic oxygen |
| DE3900261A1 (de) | 1988-05-31 | 1989-12-07 | Bayer Ag | Substituierte 4-(chinolin-2-yl-methoxy) phenyl-essigsaeure-derivate |
| US5332840A (en) | 1993-05-27 | 1994-07-26 | Bristol-Myers Squibb Company | Method for preparing a benzaldehyde intermediate |
| WO1995034304A1 (en) | 1994-06-10 | 1995-12-21 | Nauchno-Issledovatelsky Institut Farmakologii Rossiyskoi Akademii Meditsinskikh Nauk | Pharmacologically active 2-mercaptobenzimidazole derivatives |
| DE19529612A1 (de) | 1995-08-11 | 1997-02-13 | Merck Patent Gmbh | Sulfonyl- oder Sulfinyl-benzoylguanidin-Derivate |
| PT876394E (pt) | 1995-12-13 | 2001-08-30 | Lepetit Spa | Preparacao de (11beta,16beta)-21-(acetiloxi)-11-hidroxi-2'-metil-5'h-pregna-1,4-dieno¬17,16-d|-3,20-diona |
| US5968826A (en) | 1998-10-05 | 1999-10-19 | Isis Pharmaceuticals Inc. | Antisense inhibition of integrin α4 expression |
| TWI258462B (en) | 1999-12-17 | 2006-07-21 | Astrazeneca Ab | Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same |
| EP4101846B1 (en) | 2003-04-11 | 2023-08-02 | PTC Therapeutics, Inc. | 1,2,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease |
| WO2008067480A2 (en) | 2006-11-29 | 2008-06-05 | Nationwide Children's Hospital | Myostatin inhibition for enhancing muscle and/or improving muscle function |
| UA104147C2 (uk) | 2008-09-10 | 2014-01-10 | Новартис Аг | Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань |
| CN102341385B (zh) | 2009-03-09 | 2014-01-15 | 大鹏药品工业株式会社 | 能够抑制前列腺素d合酶的哌嗪化合物 |
| EP2556083A4 (en) | 2010-04-05 | 2013-12-04 | Validus Biopharma Inc | NONHORMONAL STEROID MODULATORS OF NF-KAPPA-B FOR DISEASE TREATMENT |
| WO2012053994A2 (en) | 2010-10-20 | 2012-04-26 | The Thailand Reserach Fund | Ecdysteroid analogues having plant growth promoting activity |
| RS56739B1 (sr) | 2010-11-18 | 2018-03-30 | Technion Res & Dev Foundation | Aminoglikozidi i njihova upotreba u tretiranju genetskih poremećaja |
| CN107496899A (zh) | 2011-09-29 | 2017-12-22 | 梅约医学教育与研究基金会 | 芳族阳离子肽和使用它们的方法 |
| EP2708535A1 (en) | 2012-05-11 | 2014-03-19 | Les Laboratoires Servier | Agents for treating disorders involving modulation of ryanodine receptors |
| WO2013184527A1 (en) | 2012-06-05 | 2013-12-12 | Capricor, Inc. | Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy |
| EP2945643A4 (en) | 2013-01-15 | 2017-04-26 | Phasebio Pharmaceuticals, Inc. | Therapeutic agents, compositions, and methods for glycemic control |
| EP2948437B1 (en) | 2013-01-26 | 2021-11-03 | Epirium Bio Inc. | Approach for synthesis of catechins |
| US9862945B2 (en) | 2013-04-20 | 2018-01-09 | Research Institute At Nationwide Children's Hospital | Recombinant adeno-associated virus delivery of exon 2-targeted U7SNRNA polynucleotide constructs |
| ZA201407536B (en) | 2013-10-21 | 2017-09-27 | Ems Sa | Parenteral pharmaceutical composition containing cosyntropin |
| PT3159409T (pt) | 2014-06-17 | 2020-01-21 | Nippon Shinyaku Co Ltd | Ácido nucleico anti-sentido para utilização no tratamento da distrofia muscular de duchenne |
| EP2960336A1 (en) | 2014-06-27 | 2015-12-30 | Genethon | Efficient systemic treatment of dystrophic muscle pathologies |
| WO2016059507A1 (en) | 2014-10-13 | 2016-04-21 | Kamavarapu Sarath Kumar | Improved process for the preparation of high pure metformine |
| KR102799163B1 (ko) | 2015-09-17 | 2025-04-21 | 더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 | Galgt2 유전자 치료 방법 및 물질 |
| AU2016333963C1 (en) | 2015-10-07 | 2021-05-27 | The Salk Institute For Biological Studies | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof |
| CA2971303C (en) | 2016-06-21 | 2026-03-03 | Bamboo Therapeutics, Inc. | Optimized mini-dystrophin genes and expression cassettes and their use |
| CA3024153A1 (en) | 2016-06-30 | 2017-11-30 | Sarepta Therapeutics, Inc. | Processes for preparing phosphorodiamidate morpholino oligomers |
| CA3043184A1 (en) | 2016-11-10 | 2018-05-17 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| EP3612191B1 (en) | 2017-04-19 | 2026-03-11 | Cedars-Sinai Medical Center | Methods and compositions for treating skeletal muscular dystrophy |
| WO2019079386A1 (en) | 2017-10-17 | 2019-04-25 | Sarepta Therapeutics, Inc. | CELL PENETRATION PEPTIDES FOR ANTISENSE ADMINISTRATION |
| CA3098624A1 (en) | 2018-05-11 | 2019-11-14 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| IT201900003281A1 (it) | 2019-03-06 | 2020-09-06 | Chemi Spa | Processo per preparare {6-[(dietilammino)metil]naftalen-2-il}metil [4-(idrossicarbamoil)fenil]carbammato ad elevata purezza |
| WO2021025899A1 (en) | 2019-08-02 | 2021-02-11 | Sarepta Therapeutics, Inc. | Phosphorodiamidate morpholino oligomer pharmaceutical compositions |
| AU2020392243A1 (en) | 2019-11-28 | 2022-06-16 | Regenxbio Inc. | Microdystrophin gene therapy constructs and uses thereof |
| WO2021231630A1 (en) | 2020-05-13 | 2021-11-18 | Edgewise Therapeutics, Inc. | Substituted pyridazinone for use in the treatment of neuromuscular diseases |
-
2022
- 2022-02-21 EP EP22382147.1A patent/EP4230196A1/en not_active Withdrawn
-
2023
- 2023-02-20 IL IL315130A patent/IL315130A/en unknown
- 2023-02-20 PT PT237052907T patent/PT4482481T/pt unknown
- 2023-02-20 AU AU2023222467A patent/AU2023222467A1/en active Pending
- 2023-02-20 KR KR1020247031001A patent/KR20240150792A/ko active Pending
- 2023-02-20 ES ES23705290T patent/ES3061083T3/es active Active
- 2023-02-20 DK DK23705290.7T patent/DK4482481T3/da active
- 2023-02-20 EP EP23705290.7A patent/EP4482481B1/en active Active
- 2023-02-20 PL PL23705290.7T patent/PL4482481T3/pl unknown
- 2023-02-20 MX MX2024010235A patent/MX2024010235A/es unknown
- 2023-02-20 CN CN202380032731.1A patent/CN118973560A/zh active Pending
- 2023-02-20 WO PCT/EP2023/054140 patent/WO2023156645A1/en not_active Ceased
- 2023-02-20 JP JP2024548769A patent/JP2025508761A/ja active Pending
- 2023-02-20 US US18/839,918 patent/US20250152567A1/en active Pending
- 2023-02-20 CA CA3244747A patent/CA3244747A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| DK4482481T3 (da) | 2026-02-02 |
| MX2024010235A (es) | 2024-09-19 |
| ES3061083T3 (en) | 2026-03-31 |
| JP2025508761A (ja) | 2025-04-10 |
| EP4230196A1 (en) | 2023-08-23 |
| AU2023222467A1 (en) | 2024-09-26 |
| KR20240150792A (ko) | 2024-10-16 |
| EP4482481A1 (en) | 2025-01-01 |
| US20250152567A1 (en) | 2025-05-15 |
| CA3244747A1 (en) | 2023-08-24 |
| CN118973560A (zh) | 2024-11-15 |
| PT4482481T (pt) | 2026-02-16 |
| IL315130A (en) | 2024-10-01 |
| WO2023156645A1 (en) | 2023-08-24 |
| EP4482481B1 (en) | 2025-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE063145T2 (hu) | Deuterált vegyületek rákos megbetegedések kezelésében történõ alkalmazásra | |
| EP4041212C0 (en) | MEK INHIBITORS FOR THE TREATMENT OF HANTAVIRUS INFECTIONS | |
| PT3902803T (pt) | Inibidores aza-heterobicíclicos de mat2a e métodos de utilização para o tratamento do cancro | |
| EP4236831C0 (en) | BODY LIGHT THROMBUS TREATMENT SYSTEM | |
| EP4570877A4 (en) | SURFACE TREATMENT AGENT | |
| EP4509551A4 (en) | SURFACE TREATMENT AGENT | |
| HUE058931T2 (hu) | Pilokarpin hidroklorid alkalmazása presbyopia kezelésére | |
| MX2018005694A (es) | 2- (1h-indazol-3-il) -3h-imidazo[4,5-c] piridinas y usos antiinflamatorios de las mismas. | |
| PL3972643T3 (pl) | Antagoniści układu dopełniacza do stosowania w sposobach leczenia neuropatii paraproteinemicznych | |
| EA202192746A1 (ru) | Гетероциклические соединения и их применение | |
| HRP20260406T1 (hr) | Lumateperon za primjenu u liječenju shizofrenije | |
| PL4161528T3 (pl) | Kombinacja ruksolitynibu z incb057643 do stosowania w leczeniu nowotworów mieloproliferacyjnych | |
| DK4419526T3 (da) | Heterocykliske forbindelser til anvendelse i behandlingen af cancer | |
| IL289371A (en) | Methylthioninium for use in the treatment of synaptopathies | |
| IL289758A (en) | Ferroportin-inhibitors for the use in the prevention and treatment of kidney injuries | |
| EP4493175A4 (en) | MIRDAMETINIB TREATMENT | |
| IL283899A (en) | Combinations of a hdm2-p53 interaction inhibitor and a bcl2 inhibitor and their use for treating cancer | |
| DK4340842T3 (da) | Sotorasib til anvendelse ved behandling af kræft | |
| MA51821A (fr) | Inhibiteurs de la thiorédoxine réductase à utiliser dans le traitement du cancer | |
| EP4299677A4 (en) | SURFACE TREATMENT AGENT | |
| PT4482481T (pt) | Compostos para uso no tratamento de distrofinopatias | |
| IL325421A (en) | Combinational treatment | |
| PL4182311T3 (pl) | Pochodne 1-metylo-1h-pirazol-3-ilu do zastosowania w leczeniu chorób neowaskularnych | |
| EP3946348A4 (en) | PDE9 INHIBITORS FOR THE TREATMENT OF SICKLE CELL DISEASE | |
| EP4269468A4 (en) | SURFACE TREATMENT AGENT |